White House Author
Anne Wojcicki brings to 23andMe a 10-year background in healthcare investing, focused primarily on biotechnology companies. Anne left the investing world with the hope that she could have a positive impact on research and medicine through 23andMe. From her vantage point, Anne saw a need for creating a way to generate more information - especially more personalized information - so that commercial and academic researchers could better understand and develop new drugs and diagnostics. By encouraging individuals to access and learn about their own genetic information, 23andMe will create a common, standardized resource that has the potential to accelerate drug discovery and bring personalized medicine to the public.